capital raising !, page-45

Another CR... Well, sadly "cash hungry" is the definition of small biotechs... but for a reason here. We want to have ample funding in place well in advance of conducting a clinical trial, so this raise makes sense in that regard. That said, I'll be very disappointed if this CR turns out to be excessively unfavourable to current holders.

Regarding BLTOB, I agree with J8: HCV trial is the determining factor here, not the nature of the CR.

I know I probably sound like a broken record when saying this, but PATIENCE, everyone. By all indications, ddRNAi is a sound technology, with a number of characteristics unique among the genetic therapies currently being investigated worldwide. Give it time - Rome wasn't built in a day.